Introduction. Liver cirrhosis is one a most frequent causes of death in Mexico. Chronic alcohol intake is among the main etiologies for liver disease and is highly associated to cirrhosis mortality. At the same time Mexico is the first place worldwide in prevalence of obesity. Although both causes of liver disease coincide epidemiologically, no characterization of their interaction is available. We aimed to describe the interactions of a high fat diet (HFD) and alcohol intake at the histopathologic level in the liver. Aim. To identify histopathological changes in the liver associated with a HFD concomitantly with a chronic alcohol intake in mice. Material and methods. Six groups of C57BL/ 6, 8 week-old, male mice were obtained: (C) control, (EtOH) ethanol, (HFD) high fat diet, (EtOH + HFD) ethanol + HFD, these groups received 4 months of treatment. (HFD&EtOH): 1°HFD followed by 2°Etanol and, (EtOH&HFD): 1°Ethanol followed by 2°HDF: these two groups received the first treatment for 4 months followed by the second treatment for another 4 months. Results. Histopathologic changes were observed in the liver depending on the treatment received. EtOH group showed slight architectural changes compared to C but did not show steatosis. HFD had microvesicular-focal steatosis located in hepatocytes by the portal area (TP). EtOH + HFD exhibited a worsen impairment in architecture compared with HFD showing microvesicular-focal steatosis in hepatocytes located by the TP. In contrast HFD & EtOH showed microvesicular-focal steatosis in hepatocytes by the central vein (VC), whereas EtOH & HFD had macrovesicular-difuse steatosis in hepatocytes at both locations. No signs of fibrosis were observed. Conclusion. Changes in liver architecture depend on the insults received as well as the interaction between them; specific patters of liver damage according to both the insult and the hepatocyte location among the liver acinus were shown without fibrosis. In Introduction. Cirrhosis is the fourth cause of death in Mexico, a year more than 28,000 deaths occur because of this, it is considered a public health problem. Decompensated cirrhotic patients are the most frequent internment and one of the main causes of consultation in gastroenterology services cause. Objective. Determine the main causes of decompensated liver cirrhosis in patients hospitalized in the Hospital Juárez de México. Material and methods. A retrospective, longitudinal and descriptive study where patients were hospitalized in the Gastroenterology Service diagnosed with liver cirrhosis of any etiology were included was made; decompensation requiring income from January to December 2015. Results. 112 records were reviewed by 2015. The average age was 50 years predominance of male gender. The most frequent causes were alcohol (66.96%), hepatitis C (15.17%) autoimmune liver disease (10.71%) NASH (7.14%). Predominant complications were: variceal gastrointestinal bleeding (48.21%), encephalopathy (27.67%), spontaneous peritonitis (16.96%), hepatorenal syndrome (5.35%), and refractory ascites (1.78%). The total number of deaths was 38 cases: 68.42% male and 31.57% female; its causes were variceal gastrointestinal bleeding (36.84%), septicemia (23.68%) hepatic encephalopathy (18.42%), spontaneous bacterial peritonitis (13.15%) pneumonias (5.26%) hepatorenal syndrome (2.62%). Conclusions. In the Hospital Juárez de México the main cause of hospital admission was variceal gastrointestinal bleeding, followed by encephalopathy; of these the main cause of death was observed by variceal gastrointestinal bleeding and septic shock. Alcoholism remains the main etiology of cirrhosis predominating in males, as reported in epidemiological studies of Mexico. The authors express no conflicts of interest.
Background. Non-Wilsonian hepatolenticular degeneration (NWHD) is a neurological syndrome characterized by Parkinsonism, ataxia, cerebellar symptoms, and neuropsychiatric and cognitive disorders. It has been described in 2% of patients with chronic liver disease. Its physiopathology is not currently clear, but manganese deposits seem to be crucial. Its definite treatment has not been determined. Liver transplant is a therapeutic option, although its prognosis is variable. Case report. A 53-year old female was referred to the Neurology outpatient clinic due to dysarthria. The patient had no family history of liver diseases nor a personal history of allergies, blood transfusions or drug addictions. The patient's condition started on 2013 with self-limiting dysarthria and absence seizures. In October 2014, the patient experienced the same clinical presentation, in addition to episodic falling syndrome, reason why the patient sought medical attention. A Parkinsonian syndrome, pancerebellar syndrome, dysarthria, pyramidal syndrome and atavistic reflexes were found on the physical examination. Lab tests showed liver tests abnormalities and thrombocytopenia (Table 1 ). The patient was diagnosed with liver cirrhosis (Child-Pugh B [9 points] and MELD [14 points]). The viral hepatitis screening, iron profile and autoimmune liver disease serology tests were negative. Urine copper and serum ceruloplasmin levels were within normal ranges. The magnetic resonance showed an increased signal density of the basal ganglia, predominantly of the putamen and globus pallidus (T1-weighted sequence, Figure 1 ). The abdominal CT scan showed chronic liver damage. 3D reconstruction showed a spontaneous portosystemic shunt. Discussion. HWND is an unusual neurogenerative disease in patients with liver cirrhosis. Its clinical findings are similar to those of Parkinson's disease, with imaging characteristics suggestive of Wilson's disease. Early detection is vital to continue with the diagnostic approach and to define the most appropriate treatment. The prognosis for these patients is uncertain since no impact has been shown on neuropsychiatric symptoms.
DECOMPENSATED LIVER DISEASE; ALERT FOR FINDING MINIMAL HEPATIC ENCEPHALOPATHY (MHE)
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Introduction. EHM is a liver decompensation underestimated in the context of care and patient follow-up with cirrhosis, targeted epidemiological studies are needed to this specific group, in order to optimize strategies for prevention and early intervention. Objective. visual, alcohol intake, antibiotics or sedatives in the previous 3 months, using psychometric tests EHM PHES diagnosis was made, demographic, clinical, biochemical and prognostic data analyzed by SPSS 20.0 is collected, it was considered statistically significant p < 0.05. Results. The final sample consisted of 72 patients, 40.3% EHM, 75% women, basic education 51.7%, autoimmune ethology 41%, with ascites (22.2%) with a risk for the development of EHM (OR 1.76, 95% CI. 9-3.4 P 0.077) without ascites (77.8%) (OR 0.54, 95% CI 321-919 P 0.040), Child Pugh A 31% (95% CI OR.29 -109-797-P 0.27), Child Pugh BC (OR 1.67, 95% CI 1.08-2.41 P 0.27), Baveno V (3,4,5) (OR 1.44, 95% CI .970-2.15 P 0.102), MELD < 12 51% (OR 95% .208 -. 070 to 619-P.004) ≥ 13 48.3% (OR 2.18, 95% CI -1.12-3.97 P 0.007). Conclusion. The main causes associated with EHM was the presence of ascites as independent risk factor, clinical and biochemical data in its isolated evaluation no significant association was found decompensated disease was associated with the development of EHM mainly with the MELD model. Background. Elastography has not been validated for non-cirrhotic liver disease, which is not associated with liver fibrosis, patients who progress to cirrhosis in cases of in/outflow obstruction are not detected easily. Objectives. To assess the degree of liver and spleen stiffness by elastography in hardness with portal hypertension without cirrhosis: portal vein thrombosis (PVT) and Budd-Chiari (SBC) syndrome. Correlate the value of fibroscan with time evolution and the degree of portal hypertension through the presence of esophageal varices. Material and methods. Cross-sectional study in which patients with PVT/SBC were included, during February to July 2015, elastography of liver and spleen were performed with fibroscan (computer-Ecosens-502), fat measurement was done with CAP. Records were reviewed for demographic and clinical data. Results. 18 patients, 9 men (50%) were included. The mean age was 41 years old and 5 patients had a splenectomy history. Distributed pathology: PVT in 15 patients (83%) and Budd-Chiari syndrome in 3 patients (17%). PVT patients had a mean of 6.7 kPa (2.7-19.1) and . Two patients with PVT had > 15 kPa, and all three SBC patients had > 15 kPa. Therefore 5 patients were diagnosed with cirrhosis elastography. Nobody was diagnosed with liver cirrhosis at the time of the study. Eleven patients (61%) had esophageal varices (endoscopy) without statistical significance by correlating liver or spleen elastography in the presence of esophageal varices. Although more than half of the patients have varices, only 1 patient had bleeding episode (PVT). Increased liver stiffness was independent to the years of evolution of the disease. Conclusions. The fibroscan is useful for diagnosis liver cirrhosis in patients who have not presented indication for biopsy or decompensation. Patients with PVT have low values kPa (F1-F3) compared to . Probably the obstruction of the hepatic veins is more fibrogenic than portal obstruction, although there is no correlation between liver or spleen elastography with the presence of esophageal varices.
DETERMINATION OF LIVER AND SPLEEN STIFFNESS BY ELASTOGRAPHY (FIBROSCAN) IN PORTAL HYPERTENSION WITHOUT CIRRHOSIS (PORTAL VEIN THROMBOSIS/BUDD-CHIARI SYNDROME) THEIR CORRELATION AND DEPENDENCE WITH ESOPHAGEAL VARICES
DOMÍNGUEZ
GASTROINTESTINAL BLEEDING VARICEAL: BE PERFORMED WITH DIAGNOSTIC LABORATORY STUDIES?
Introduction. Upper gastrointestinal bleeding is defined as that produced before the angle of Treitz, between its causes include gastric ulcer, duodenal ulcer, gastric cancer and variceal hemorrhage, mortality ranges from 3.5 to 7.4%. Objective. Child A patients developed some kind of bacterial infection vs. 36.2% of Child B or C (HR = 3.4; 95% CI: 1.5-7.6, P = 0.001). In the cohort of patients exposed to PPI, 31.8% developed some kind of bacterial infection vs. 14.5% in the non-exposed cohort (HR = 2.1; 95% CI: 1.1-4.3; P = 0.03). The median of time for develop infections in the exposed cohort to PPI was lower than in the non-exposed: 10 months (interquartilic range 7-12 months) vs. 16 months (interquartilic range 6-28 months) respectively (P = 0.02) (Figure 1 ). In the multivariate analysis, the state of decompensated cirrhosis was no significant, while the chronic consumption of PPI was associated with an increase in the risk of infections (HR = 3.38; 95% CI: 1.1-10.6, P = 0.037). Conclusions. The chronic use of PPI in patients with cirrhosis is a risk factor associated with the development of bacterial infections.
PROTEIN-CALORIE MALNUTRITION NEGATIVELY IMPACTS ON THE QUALITY OF LIFE OF PATIENTS WITH CIRRHOSIS
ROJAS-LOUREIRO G,* PÉREZ-REYES E,* SERVÍN-CAAMAÑO AI,** ROJAS-LOUREIRO G,* PÉREZ-REYES E,* SERVÍN-CAAMAÑO AI,** ROJAS-LOUREIRO G,* PÉREZ-REYES E,* SERVÍN-CAAMAÑO AI,** ROJAS-LOUREIRO G,* PÉREZ-REYES E,* SERVÍN-CAAMAÑO AI,** ROJAS-LOUREIRO G,* PÉREZ-REYES E,* SERVÍN-CAAMAÑO AI,* Background. Protein-calorie malnutrition (PCM) is a common complication in patients with cirrhosis. The chronic liver disease questionnaire (CLDQ) was designed specifically to evaluate the quality of life in patients with chronic liver disease. Objective. To compare if there is impairment of quality of life of cirrhotic patients with PCM vs. us those well-nourished. Material and methods. An observational, analytic, transversal study which included patients with cirrhosis for any etiology.
We evaluated the nutritional status through the Global Subjective Assessment (GSA) and we applied the CLDQ questionnaire. We compared between groups using Student's t test. Results. Were included 127 patients, 70 women (55.1%). About the nutritional state according to the GSA, 58 patients (45.7%) were well-nourished, 66 patients (52%) had mild-moderate malnutrition, 3 patients (2.4%) had severe malnutrition. According with the CLDQ questionnaire, patients with malnutrition had more significant symptoms (Table 1) . Conclusions. The PCM impairs the quality of life in patients with cirrhosis. The CLDQ questionnaire is a useful tool to evaluate the quality of life in the clinical setting. Background and aims. Quality of life (QoL) is affected in patients with cirrhosis. It has been observed a potential association between nutritional status and QoL in cirrhosis. The aim of this study is to determine the association between nutritional status and QoL in patients with cirrhosis. Material and methods. We evaluated 66 patients with cirrhosis, nutritional status was classified according to Subjective Global Assessment as well nourished, risk of malnutrition and malnutrition. A questionnaire of frequency of food consumption was applied. QoL was assessed by Spanish version of Liver Disease Quality of Life Questionnaire. Analysis of QoL domains and nutritional status was performed by one way ANOVA. Results. The 50% were female, mean of body mass index and age were 27.6 ± 5.9 kg/ m 2 and 58 ± 10 years respectively. Most of the patients 27.3% were A Child-Pugh Score, 29% B and 6% C. Prevalence of well-nourished patients was 32%, while patients in risk of malnutrition was 53% and malnourished patients was 15.2%. Mean global QoL was 3.9 ± 0.8; means of each domain of questionnaire was shown in table 1. Malnourished patients presented lower score of global QoL, as well as activity, fatigue and emotional symptoms (Table 1) . There is no association between food consumption and QoL. Conclusion. In patients with cirrhosis, QoL is associated with nutritional impairment. However frequency of foof consumption was not related.
ASSOCIATION BETWEEN NUTRITIONAL STATUS AND QUALITY OF LIFE IN PATIENTS WITH CIRRHOSIS
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-(II.11) Table 1 .
Domain
All patients μ ± SD Well-nourished μ ± SD Malnourished μ ± SD P Abdominal symptoms 5.4 ± 1.8 5. 
EFFECT OF THE COMBINATION OF CARVEDILOL AND SIMVASTATIN IN PORTAL PRESSURE GRADIENT IN PATIENTS WITH CIRRHOSIS AFTER VARICEAL BLEEDING (SECONDARY PROPHYLAXIS)
DOMÍNGUEZ-WAKIDA A, GASCA-PONCE M, MIGUEL-CRUZ A,  DOMÍNGUEZ-WAKIDA A, GASCA-PONCE M, MIGUEL-CRUZ A,  DOMÍNGUEZ-WAKIDA A, GASCA-PONCE M, MIGUEL-CRUZ A,  DOMÍNGUEZ-WAKIDA A, GASCA-PONCE M, MIGUEL-CRUZ A,  DOMÍNGUEZ-WAKIDA A, GASCA-PONCE M, MIGUEL-CRUZ A,  SÁNCHEZ-ÁVILA F, CASANOVA-SÁNCHEZ I,  SÁNCHEZ-ÁVILA F, CASANOVA-SÁNCHEZ I,  SÁNCHEZ-ÁVILA F, CASANOVA-SÁNCHEZ I,  SÁNCHEZ-ÁVILA F, CASANOVA-SÁNCHEZ I,  SÁNCHEZ-ÁVILA F, CASANOVA-SÁNCHEZ I,  MOCTEZUMA-VELÁZQUEZ C, LÓPEZ-MÉNDEZ E  MOCTEZUMA-VELÁZQUEZ C, LÓPEZ-MÉNDEZ E  MOCTEZUMA-VELÁZQUEZ C, LÓPEZ-MÉNDEZ E  MOCTEZUMA-VELÁZQUEZ C, LÓPEZ-MÉNDEZ E  MOCTEZUMA-VELÁZQUEZ C, LÓPEZ-MÉNDEZ E  DEPARTAMENTO Background. There are not background of carvedilol/simvastatin in secondary prophylaxis. Objective. Evaluate the effect of the combination of carvedilol/simvastatin in the hepatic venous pressure gradient (HVPG) in secondary prophylaxis after variceal bleeding. Material and methods. Preliminary report of seven cirrhotic patients who failed to secondary prophylaxis (propranolol/endoscopic variceal ligation). Measurement (HVPG) were performed once the variceal bleeding was controlled and vasoactive drugs were stop, patients received 6.25 mg/day of carvedilol and 20 mg/day of simvastatin. After a week, the medication dose increased in accordance to the heart rate, blood pressure and adverse effects. A second HVPG measurement was performed after two weeks of treatment and the patients were grouped according to the HVPG response: a) Complete-responders: decreased by >20% of the HVPG or final HVPG < 12 mmHg, b) Partial-responders: decreased by > 10% but < 20% and > 12 mmHg; c) No-responders: without decreased in HVPG. Results. Age was 63 ± 21 years old. The more frequently etiology was autoimmune cholangitis 42.86%, followed by autoimmune hepatitis 28.57%, NAFLD 14.9% and cryptogenic cirrhosis 14.9%. The mean of HVPG decreased for the complete responders (n = 2) and was -25.9%, with a mean dose of 9.4 ± 3.1 mg/day of carvedilol and 30 ± 10 mg/day of simvastatin. Partial responders (n = 3), the mean of HVPG decreased by -23.8%, with a mean dose of 10.4 ± 2.9 mg/day of carvedilol and 40 mg of simvastatin. No responders (n = 2) the HVPG increased +13.3%, mean doses 18.8 ± 6.3 mg/day of carvedilol and 40 mg of simvastatin. None of the patients presented deleterious effects in systemic hemodynamics and adverse effects. Conclusions. Our data in seven patients show: 71.4% of the patients responded to the medication. This is not a randomized study therefore it cannot be evaluated drug action independently. We suggest that the total responders should be followed without endoscopic control. Partial responders could be follow with both medication and endoscopic control. No responders needs only endoscopic control. Further randomized studies are needed to evaluate and compare the effect of carvedilol versus propranolol in secondary prophylaxis. Background and aim. The importance of knowing liver function in patients with liver cirrhosis has led to create different prognostic scales both mortality and decompensation. The ALBI score has been used in patients with hepatocellular carcinoma (HCC), however could also be used in patients with liver cirrhosis without HCC. Primary objective. To assess the use of ALBI scale prognosis in liver cirrhosis decompensation. Material and methods. Cross-sectional descriptive retrospective in patients with diagnosis of liver cirrhosis from January 2015 to January 2016 hospitalized by variceal upper gastrointestinal bleeding accompanied by hepatic encephalopathy (HE) and / or spontaneous bacterial peritonitis (SBP). ALBI score was used according to grade I ≤ -2.6, grade II > -2.6 -≤ -1.39 and grade III > -1.39. They were classified according to etiology of bleeding in large esophageal varices of Baveno (LEVB) isolated gastric varices 1 (IGV1), gastroesophageal varices (GOV2), LEVB-GOV1, LEVB-GOV2. Only patients with etiologies alcoholic, steatohepatitis, hepatitis C virus, autoimmune hepatitis and primary biliary cirrhosis were included and other causes were excluded. Average percentages and analysis were applied. Results. 64 patients, 35 male (54.6%) and mean age 55.8 years, female 29 (45.3%) with mean age 69.9 years were analyzed. Nine patients were obtained in grade I (LEVB 6, IGV1 2, GOV2 1 without HE or SBP), grade II were 33 patients (LEVB 17, IGV1 2, GOV2 6, LEVB-GOV1 2, LEVB-GOV2 6, EH 6 and PBE 1), and the grade III were 22 (LEVB 19, GOV2 2, LEVB-GOV1 1, HE 9 and SBP 2). Conclusions. According to the results obtained the degree of ALBI correlates with greater decompensation, according to this study grade III had a higher number of hepatic encephalopathy, spontaneous bacterial peritonitis associated with upper gastrointestinal bleeding and vice versa for grade I, so this scale could be used to forecast decompensation. (Figures 1 and 2 ). Patients have received two sessions within three months, with hemoglobin stabilization and without the presence of bleeding or the need of transfusions, being considered this endoscopic therapy the most effective procedure at the moment. A hemoglobin increase was found, with a lower number of sessions and decrease rate in complications. Conclusion. For patients with GAVE, and especially for those refractory to conventional treatments, ablation therapy with Radiofrequency is a new endoscopic option with promising results which require a greater evaluation.
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Introduction.
Spontaneous bacterial peritonitis is a mayor complication of liver cirrhosis. Among the risk factors is an advanced degree of liver failure, hyponatremia < 125 mmol/L, low albumin, MELD > 22. The use of nonselective beta-blockers may alter the hemodynamic profile, increasing the risk of bacterial translocation and thus the risk of spontaneous bacterial peritonitis. Material and methods. The aim of the study was to determine whether the use of non-selective beta blockers in patients with decompensated cirrhosis is an independent risk factor for the development of spontaneous bacterial peritonitis. A study of cases and controls, which included patients with decompensated cirrhosis diagnosis either hepatic encephalopathy, variceal bleeding or ascites was performed. Two groups one peritonitis and one without spontaneous bacterial peritonitis were assigned, we studied risk factors such as non-selective beta blockers, proton-pump inhibitor, low albumin, variceal hemorrhaging, advanced liver failure determined by scale of ChildPugh grade Meld. Multivariate analysis was performed as statistical test. Results. Of the 82 selected patients, 4 were excluded in total presence of malignancy. The average age was 54 years in both groups, with a predominance of the female gender, it was determined that the use of non-selective beta-blockers was not an independent risk factor for the development of spontaneous bacterial peritonitis with a 0.177 p. As the use of proton-pump inhibitor was not a risk factor with p.126. Conclusions. The use of nonselective beta-blockers as primary or secondary prophylaxis is not an independent risk factor for the development of spontaneous bacterial peritonitis. This study doesn't have any sponsor. Background and aim. The prevalence of osteoporosis / osteopenia ranges in 30% of patients with primary biliary cirrhosis (PBC) and is associated with fractures in 7-35%. The imbalance between resorption and bone remodeling is the cornerstone of the pathophysiology since deficiency osteocalcin is documented; additionally, cholestasis interferes on osteoblast function and promotes apoptosis, and limit intestinal absorption. Intake corticosteroids, hypogonadism, vitamin D deficiency and malnutrition are concomitant factors to its progression. However, although there are many studies on coexistence and established treatment, there is no information on the natural history of osteoporosis in PBC, so our goal is to prove its existence from the early stages of the disease. Material and methods. It is a retrospective, observational and descriptive study, which the medical records of 16 patients with histopathologic diagnosis of CBP were analyzed, 2 patients were excluded due course of sobreposition syndrome with autoimmune hepatitis, 1 report liver cirrhosis in histopathology report and 1 had no bone densitometry report. Results. 13 patients were analyzed analyzed, the average age is 57.2 years, 100% are female 7 (53.8%) reported osteopenia on densitometry (DE < 1.5), 4 (30.7%) reported osteoporosis (DE ≤ 2) and 2 (15.3%) were reported normal. No patient has reported associated fracture. Histopathology studies reported in phase I 31% (4) and stage II 69% (9). Conclusions. Given the results of the reports of bone densitometry DE < 1.5 at 84.5% at diagnosis, confirmed by histopathology in early stages (stages I and II) we conclude that the bone injury in CBP courses from early stages of the disease what must be taken into account to initiate appropriate treatment from diagnosis of CBP. Background. Cholestatic liver diseases are among the most serious diseases affecting the liver. Treatments are not optimized; more research is necessary in order to improve treatment options. It has been observed that hepatocyte growth factor (HGF) can display protective effects that could support conventional therapies against cholestasis. Objective. The aim of this work was to address the protective effect of HGF in cholestasis induced by alpha-naftylisotiocianate (ANIT). Material and methods. CD1 mice were treated with ANIT (60 ug/kg, ig), 24 h after the toxic treatment, 10 ug/kg, iv of HGF was administrated. Animals were sacrificed 24 h after HGF treatment. Liver function test, and routing H&E staining were performed. Main molecular markers of damage and protection were addressed by Western blotting and RTPCR. Results. ALT, AST and ALP were increased by ANIT treatment, and HGF reduced these parameters. Histology showed tissue damage, particularly necrosis and inflammatory infiltration. HGF improved these findings. Molecular studies revealed the increment of Abcc3, Abcc2 and Cyp7a1 by HGF in comparison with ANIT alone treatment, this effect was associated by the activation of NRF2. Conclusions. HGF induced a protective effect decreasing necrosis and inflammation, and improving the main liver function markers, this effect was associated to an increment in the expression of phase 3 detoxification proteins. HGF could be considered as adjuvant in the treatment of cholestasis. CONACyT 252942.
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HGF INDUCES A PROTECTIVE EFFECT IN
IV. VIRAL HEPATITIS
ANALYSIS OF DIFFERENTIAL PROTEOMIC PROFILES EXPRESSION WITH GALLIC ACID IN HUH7 CELLS INFECTED WITH HEPATITIS C VIRUS
Introduction and aim. Currently, the hepatitis C virus (HCV) proteome and its interrelation with the proteome of HCV-infected cells have been studied to the search for new antiviral antioxidants agents. Therefore, we evaluated the gallic acid (GA) effect, a phenol present in plants and fruits with anti-HCV capacity, on the proteome of cells that expressing viral proteins (Huh7-HCV). Material and methods. Huh7-HCV cells were exposed to 200 μM GA for 0-72 h. After each time, total proteins were extracted and 50 mg were resolved in twodimensional electrophoresis gels to separate by isoelectric point (pI) and molecular weight (MW) in SDS-PAGE 12%. Gels were analyzed by PD-QUEST-v8.0.1 software. Protein differential expression was analyzed and were elucidated according to pI-PM using TagIdent software to identify proteins associated with HCV. Experiments were performed in triplicate and analyzed by Tukey. Results. Differential proteomic profiles were found in Huh7-HCV treated and untreated with GA at different times. Profiles denoting a basal expression of proteins that showed differential profile (35%), such as cellular stress response and antiviral activity proteins (Hsp72 and HSP7C) were identified. Also, at 24h with GA, an overexpression (30%) of proteins involved in liver regeneration, angiogenic and anti-apoptotic (GAS6, SOM2, RASF7, URP2) was observed. After 48 h of treatment, apoptotic, anti-angiogenic and mitochondrial proteins expression increased (40%) (CRLS1, AIFM1, NDUAA). Finally, at 72 h of GA exposure, we identified an overexpression (60%) of proteins related to cell protection, cell cycle and DNA repair (KAD2, ALKB8, GRB2, TNF14); that are necessary for cell survival after DNA damage, acting as a viral repressor. Conclusions. Our study identified changes in Huh7-HCV proteome in GA presence, generating information about the mechanisms of viral pathogenesis. GA decreases HCV replication and induces proteins expression in exposed cells, involved in stress response, viral activity, apoptosis, angiogenesis and tumor suppression. These results will allow identify proteins associated with HCV that could be molecular targets to treatment. Work supported by CONACyT-BASICA-CB2010-01-155082 and FONCyT-COECyT-COAH-2002-C08-C37. Background and aim. SAM decreases HCV viral expression by unknown mechanisms. SAM can regulate proteasomal activity in hepatocellular carcinoma cells. Our aim was to elucidate the mechanism(s) by which SAM decreases HCV expression, using the Huh7 hepatoma cell line expressing HCV non-structural proteins. Material and methods. Huh7 HCV-replicon cells were incubated with SAM 1mM, MG132 1 μM and mixed treatment for up to 72h. Cellular protein extracts were subjected to immunoblot analysis to detect NS5A and total ubiquitinated protein levels. Proteasome chymotrypsin-like activity was measured in HCV replicon cells upon 12-72 h of SAM exposition by using a commercial fluorogenic susbtrate for proteasome 20S Chymotrypsin like activity (Suc-Leu-Leu-Val-Tyr-AMC) measuring fluorescence every 30 min at 380 nm excitation/460 nm emission. Huh7 HCV replicon cells were exposed either with actinomycin D (4 μg/mL) or cycloheximide (50 μg/mL) and 2 h later 1 mM SAM was added. Cells were incubated at different time points (0-36 h) and then harvested to perform HCV-RNA and NS5A protein levels quantification. In addition, intracellular SAM concentration was measured by HPLC (24-72 h). Results. SAM treatment decrease NS5A protein level (65%) compared to untreated control at the same time (24-72 h). Intracellular SAM levels were higher than control cells upon 24-72 h post treatment. Chemical inhibition of total proteasome activity by MG132 reduced NS5A level (50%) and this effect was increased by SAM combined-treatment upon 24 h, since we observed that viral protein decreases even more than single treatment (83%). Ubiquitination profiles in cells treated with SAM were lower expressed than untreated cells at the same times (50-40%, 48-72 h respectively). Interestingly, SAM reduced total accumulated amount of ubiquitinated proteins from cells exposed to MG132. We found that SAM decreased the proteasome chymotrypsin-like activity (10-30%, p < 0.05) in treated cells (24-72 h), compared with untreated cells. In addition, we found that SAM-treated cells showed lower NS5A levels compared with the cells treated with cycloheximide at 24 h, and this effect was partially reverted when SAM-treated cells were exposed to cycloheximide (60% SAM, 80% CHX + SAM). Conclusions. Our findings suggest that S-adenosylmethionine indirectly reduces HCV expression by modulating ubiquitination profiles and disturbing the chymotrypsin proteasome activity required to HCV replication. This work was partially financed by CONACyT-BASICA No. I0017-155082. Authors do not have any relevant commercial relationships to disclose. Background. Reactive oxygen species (ROS) plays an important role in hepatitis C virus (HCV) down-regulation. Recently, it has been reported that hepatocyte growth factor (HGF) reduces the viral load in chronic hepatitis C patients; however, the molecular mechanism(s) involved are yet unknown. Material and methods. Transient transfection assays were performed in Huh-7 cells to overexpress the HCV proteins with pFK 1389 -NS3-3', pNS5A and pE2 plasmids and then cells were treated with 50 ng/mL of HGF for 24-48 h. Total RNA was extracted to quantify mRNA expression of superoxidase dismutase 1 and 2 (SOD1 and SOD2); methionine adenosyltransferase 1 and 2 (MAT1 and MAT2); catalase (CAT), thioredoxin (TRX), 18S ribosomal RNA and HCV-RNA by real-time PCR assay. Simultaneously, ROS levels were assessed by DHCF-DA assay at 24h. Western blot assay were performed to evaluate the protein expression levels of actin, CAT, SOD1, SOD2, MAT1A and MAT2A in cells treated with HGF for 48 h. Results. Our results indicate that gene expression of SOD1, SOD2, MAT2A, CAT and TRX was up-regulated by HGF compared with controls without treatment (16-fold, 5-fold, 4-fold, 4-fold and 1 fold-times, respectively). However, mRNA level of MAT1A were undetectable because this gene is silenced in hepatocellular carcinoma. ROS levels were diminished in pFK 1389 -NS3-3', pE2 and pNS5A transfected cells treated with HGF upon 24 h in comparison to untreated cells (14%, 10% and 40%, respectively). In pFK 1389 -NS3-3' transfected cells we could not find a differential modulation of antioxidant enzymes compared with the controls at 48 h. Interestingly, we found that HGF down-regulated NPTII protein, which is under HCV IRES control. Also, we found a down-regulation of MAT2A (30%) and up-regulation of MAT1A (27%) at 48 h upon HGF exposition compared with untreated cells. Conclusions. HGF induced mRNA levels of SOD1, SOD2, MAT2A, CAT and TRX and at the same time decreased ROS levels in cells transfected with HCV proteins. Also, HGF inhibits HCV expression levels and oxidative stress by unknown mechanisms that could involve in part a modulation of antioxidant enzymes systems and modulation of MAT1A/MAT2A enzymes relationship. This work was partially financed by CONACyT-BASICA No. I0017-155082. The authors declare that there is no conflict of interest. Background and aims. Connective Tissue Growth Factor (CTGF/CCN2) induces hepatic progenitor cells to differentiate into hepatocytes or cholangiocytes in the chronic liver damage. During the liver regeneration in rat, expression of this protein is decreased compared with the fibrotic liver, reaching levels of a healthy liver; however the expression of this peptide in the liver and serum is unknown during fibrosis reversion. Our aim was to quantify the CTGF/CCN2 protein in liver and serum during liver fibrosis reversion in an experimental model. Material and methods. 12 Wistar male 3 month old rats weighing 250 ± 20g were administered i.p. with 20 doses of CCl 4 (250 μL, 33% v/v olive oil) to induce severe fibrosis (F3), according to METAVIR score. After completing the scheme, 6 of these subjects received one month of recovery (F3 + R). A control group (F0) were included. The livers of the 3 groups were collected and the degree of fibrosis was established by histology (Sirius Red) according to METAVIR score. CTGF/CCN2 was quantified in liver tissue and serum by ELISA. The results were shown as Mean ± SD, and were analyzed using one-way ANOVA and Tukey post-hoc test. p <0.05 was considered significant. Results. Peptide levels CTGF/ CCN2 in the liver in the process of reversion of fibrosis were increased significantly compared to the group receiving the same number of administrations, reestablishing at equivalent levels to control (F0 = 2,913 ± 242; F3 = 1,629 ± 388; F3 + R = 2,807 ± 566 pg/mL n = 6), however no differences were observed between the groups at the serum level (F0 = 1,743 ± 271; F3 = 1,533 ± 487; F3 + R = 1,619 ± 255 pg/mL n = 6).
S-ADENOSYLMETHIONINE (SAM) DECREASES HEPATITIS C VIRUS (HCV) REPLICATION BY MODULATING UBIQUITINATION AND PROTEASOME ACTIVITY
NEGATIVE REGULATION OF HEPATITIS C VIRUS BY HEPATOCYTE GROWTH FACTOR IN HUH-7 CELLS
QUANTIFICATION OF CONNECTIVE TISSUE GROWTH FACTOR DURING RAT LIVER FIBROSIS REVERSION
Conclusions.
During the reversal of fibrosis, expression of the peptide CTGF/CCN2 is increased in the liver, which may be associated with regression of fibrosis and differentiation of progenitor cells to try to counteract the damage caused by CCl 4 , without changes in the protein secretion. Further studies to understand the mechanism of action of CTGF/CCN2 during reversion of liver fibrosis are needed. Acknowledgement: This study was funded by "Estímulo Antonio Ariza Cañadilla para la Investigación en Hepatología" and Consejo Nacional de Ciencia y Tecnología CB-2013-01-221137. Background and aim. Treatment of chronic infection of hepatitis C virus (HCV) with interferon-pegylated + ribavirin is recommended in guidelines from 2009, however, access to this treatment is still very limited in our country; although schemes already exist in the world safer and more effective therapeutic. The aim of this was to describe the characteristics of our patients one year after starting treatment at this center. Material and methods. Cross-sectional, observational and descriptive study. Records of patients with chronic HCV infection were analyzed. Patients with decompensated liver cirrhosis who presented contraindication to treatment were excluded. Results. 25 cases were analyzed in the last year of patients with HCV treatment. The characteristics of our patients were: men 14 (56%), mean age 44 ± 9.1 years. Genotypes: 1a (48%), 1b (16%), 1 undetermined (16%), genotype 2 (16%), genotype 4 (4%). Regarding the degree of fibrosis: 1 (4%) F1, 2 (8%) F3 and 6 (24%) F4; including 8 Child-Pugh A (80%) and 2 Child-Pugh B (20%), according to MELD, 7 patients with mortality 1.9% to 3 months and 3 patients with mortality of 6% to 3 months. 56% of patients had comorbidities: 4 (28%) HIV, 3 (21%) diabetes. Currently 12 (48%) treatment, 4 (16%) undetectable at end of treatment, 6 (24%) not early virological response, 2 (8%) suspended in week 24 and only 1 (4%) discontinued due to adverse effects. Eleven (44%) had adverse effects the most frequent thrombocytopenia 4 (36%), 4 (36%) and asthenia weakness, anemia 2 (18%) and 1 (9%) lability. Conclusions. One year after starting treatment for virus infection in our hospital hepatitis C most are male, with an average age of 44 years, the most frequent genotype 1b. 40% with some degree of fibrosis and 28% HIV. The most common adverse event thrombocytopenia. After one year, 4 concluded treatment 12 treatment and 9 suspended awaiting new molecules.
CHRONIC HEPATITIS C TREATMENT WITH DIRECT ANTIVIRAL AGENTS IN A REAL LIFE SETTING
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EXPERIENCE A YEAR OF TREATMENT IN PATIENTS WITH CHRONIC INFECTION FOR HEPATITIS C VIRUS IN HOSPITAL GENERAL DE MÉXICO
CÓRDOBA
HIGH EFFICACY (SVR) IN REAL LIFE OF DDA INTERFERON FREE ANTIVIRAL REGIMEN IN MEXICAN PATIENTS WITH CHRONIC HEPATITIS C
MALÉ-VELÁZQUEZ R, MIRELES-ÁLVAREZ CA, HERNÁNDEZ-JAIME M, MALÉ-VELÁZQUEZ R, MIRELES-ÁLVAREZ CA, HERNÁNDEZ-JAIME M, MALÉ-VELÁZQUEZ R, MIRELES-ÁLVAREZ CA, HERNÁNDEZ-JAIME M, MALÉ-VELÁZQUEZ R, MIRELES-ÁLVAREZ CA, HERNÁNDEZ-JAIME M, MALÉ-VELÁZQUEZ R, MIRELES-ÁLVAREZ CA, HERNÁNDEZ-JAIME M, Introduction. In patients with infection caused by hepatitis C virus (HCV), treatment schemes with interferon free direct antivirals (IFDA) have demonstrated to have a superior sustained viral response (SVR), adherence to treatment, adverse effects, and regression of the liver disease. Objective. Describe the SVR in patients treated with IFDA suffering from HCV. Material and methods. A prospective cohort study of patients treated with IFDA suffering from HCV were evaluated; all patients had clinical, para-clinics and image study follow up to document their viral load, SVR, adherence to treatment, fibrosis and adverse effects (AEs). SPSS software version 22 was used to determine median and interquartile to describe continuous variables and percent of categorical variables with confidence interval. Results. Information of 35 patients was collected, with a median age of 60 years, 54% women. 43% had genotype IA, 46% IB and 11% genotype 2; the median baseline viral load was 860,056 UI. 60% of the patients had cirrhosis (66% Child A, 44% Child B), 18% presented moderated fibrosis, 11% HCV without fibrosis and 11% liver transplanted. 46.6% had previous treatment (88% ribavirin + interferon, 22% triple therapy with boceprevir). 93% had SVR (IC 95% 79%-99%), 77% presented with some AEs and 7% suspended treatment due to AEs. Conclusions. SVR in our population is the same as the one reported on international literature, with few AEs and good adherence to treatment.
IS THERE LIVER FIBROSIS REGRESSION AFTER INTERFERON FREE ANTIVIRAL REGIMEN TREATMENT FOR HEPATITIS C VIRUS? RESULTS TRANSIENT ELASTOGRAPHY PRE AND POST-TREATMENT
Introduction. There are new strategies to avoid progression of the disease in patients with infection for hepatitis C (HCV Background. Autoimmune hepatitis (AIH) is a progressive inflammatory liver disease, has a broad clinical spectrum and response to immunosuppressive therapy prevents progression to cirrhosis. Objective. Determine the presentation of autoimmune hepatitis in our population. Material and methods. We conducted a retrospective cohort study of patients with autoimmune hepatitis in last 10 years and determinate the clinical, biochemical and histopatologic features. Results. Were included 32 patients, 75% female. The development of hepatitis in over 3 months was in 19/32 (60%) patients, whereas that liver failure it was the clinical form in 9/32 (28%) patients and acute hepatitis in 4/32 (12.5%). Type 1 AIH was more frequently. In chronic hepatitis 19 (60%) the evolution was insidious with non-specific characteristics cirrhosis at diagnosis in 11/32 (34%) patients. Co-morbilitiy were detected in 16 cases, of this 44% was autoimmune. All received immunosuppressive management and 25% abandoned treatment. 37% was achieved suspend the immunosuppressant or maintain minimum dose of steroid. 6% of patients die. Conclusions. In this study more than a half of cases were silent presentation and a third of this patient have advanced liver fibrosis to diagnosis. A high degree of suspicion is required for an early diagnosis and timely treatment that significantly improves the prognosis. The authors declares that there is no conflict of interest.
Background and aim. The fulminant hepatic failure (FHF) is a very severe condition in the pediatric patients, since it is a multisystemic condition that it deals with a severe damage of the hepatic function associated with hepatic necrosis and reflected (V. 01) Background. The different mechanism involved in the pathophysiology of alcoholic liver disease (ALD) alterations in cellular mediators they are modified during the development of ALD. Aim. Evaluate levels of cytokines in subjects with different pattern of alcohol consumption. Material and methods. The cross-sectional study included four groups: Group 1 control subjects; group 2 subjects with Hazardous alcohol consumption (AUDIT > 8); group 3 subjects without clinical or biochemical stigmata of liver damage; group 4 patients with cirrhosis by alcohol. Serum cytokine levels were determined by Luminex technology. For statistical analysis was performed U-Mann Whitney and we considered significant differences (p < 0.05).
Results. Included 311 subjects, the mean age was: 38 ± 10, 31 ± 11, 28 ± 12 y 47 ± 7 years, respectively (p < 0.001). Conclusion. The results show different cytokine levels being higher in the group with cirrhosis, therefore we considered that inflammation is a permanent process in alcohol consumption and is more evident in alcoholic liver disease. This work was supported in part by Program PAPIIT IA203113, PAPIIT IA200515 y PROMEP-SEP: CA302.
TLR-4 EXPRESSION IN MONOCYTES PERIPHERAL BLOOD OF ALCOHOLICS AND ALCOHOLIC CIRRHOTIC PATIENTS
Introduction. (OH) of liver damage from alcohol. Detailed medical history of each patient was realized. The control group (CT) consisted of subjects who did not consume alcohol or consumed < 10 g/day. Blood samples on one occasion (10 mL) were collected to obtain mononuclear cells by density gradient. These cells were labeling and analyzed by flow cytometry. For statistical analysis, ANOVA was performed using ortogonal analysis. Results. CT were 9 (AUDIT < 3) and mean age of 26 ± 6 years, and 1.8 gOH/day. The CiOH (4) and OH were 8. The mean age was 38 ± 15 and 48 ± 8 years, respectively, (AUDIT > 17 for both groups). Average grams of alcohol per day for liver a damage was 345 ± 11 g on patients without damage was 100 ± 34 g. The years of consumption were 28 years in both groups. Results of monocytes for CT: 10%, OH: 13%, CiOH: 16%. CD14 was 81% for all groups. While for TLR4 was CT: 0.9%, OH: 65%, CiOH: 96% p < 0.001 between controls and patients. Conclusions. TLR4 expression was significantly higher in alcoholics with and without liver damage, in peripheral blood monocytes. This receptor not only is activated in liver and also in peripheral blood therefore TLR 4 may be contributed to systemic inflammation.
PROGNOSTIC MODELS IN PATIENTS WITH ALCOHOLIC HEPATITIS
ENRÍQUEZ-COVARRUBIAS P,* SERVÍN-CAAMAÑO AI,** ENRÍQUEZ-COVARRUBIAS P,* SERVÍN-CAAMAÑO AI,** ENRÍQUEZ-COVARRUBIAS P,* SERVÍN-CAAMAÑO AI,** ENRÍQUEZ-COVARRUBIAS P,* SERVÍN-CAAMAÑO AI,** ENRÍQUEZ-COVARRUBIAS P, Introduction. There are several prognostic models to predict mortality in patients with alcoholic hepatitis (AH): The modified discriminant function Maddrey, the Glasgow's scale, ABIC score, MELD and MELD-Na. There are no studies comparing them all together. Objective. To determine which is the best model to predict mortality (first 30 days) in patients with HA. Material and methods. Data were collected from patients with HA over the past 5 years and prognostic models were calculated: Maddrey's modified discriminant function, Glasgow's scale, ABIC, MELD and MELD-Na, and 30-day survival was revised. Statistical analysis was performed using ROC curves. Results. A total of 76 patients; 72 (94.7%) were males; 58 (76.3%) had cirrhosis by ultrasound; 39 (51.3%) were treated with prednisone, and 37 (48.7%) with pentoxifylline; the overall 30-day mortality was 46 (60.5%) patients. In the COR curve analysis, the MELD, followed by MELD-Na had the best specificity and sensitivity according with the area under the curve (Figure 1 ). Conclusion. MELD and MELD-Na are the best prognostic models to predict mortality in patients with HA. Background and aim. Alcohol consumption in Mexico is a public health problem. We need to have national statistics on the reason for readmission in patients who present with this condition to work on prevention. The primary objective is to show the main causes of hospital readmission in patients with alcoholic liver disease, such as secondary objectives to demonstrate the frequency of age, sex, severity with which these patients are admitted, the average time of reentry. Material and methods. Observational retrospective epidemiological study from January 2012 to January 2015, including patients of any age and sex who were admitted to the Department of Gastroenterology of Hospital Civil de Guadalajara with previous diagnosis of liver disease by alcohol, defined as intake of 20 g of alcohol per day in women and 30 g per day in men, over one year. Epidemiological data was taken from the clinical record, carried and emptied statistical data using an electronic program and database. Performing frequency measurements of age, gender, severity by Child Pugh classification, re-entry time, causes of readmission. Results. 1,130 patients with acute/chronic liver disease diagnosis, of which 28.3% (n = 320) were secondary to alcoholic etiology and of these 28.7% (n = 92) had hospital readmission. The main cause of rehospitalization was upper gastrointestinal bleeding 29% (n = 27), followed by hepatic encephalopathy 26% (n = 24), ascites 21% (n = 19), infections 12% (n = 11), other (low gastrointestinal bleeding, acute pancreatitis, acute kidney failure) 12% (n = 11), the infection that was most documented during hospitalization was Urinary Infection in 54% (n = 21), most readmission rate was presented before the month in 52% (n = 48), the Child Pugh score C was the most occurred in the first income as in reentry. Conclusions. The upper gastrointestinal hemorrhage and hepatic encephalopathy were the main causes of hospital readmission, which occurred within the first month. We must take preventive measures to reduce such readmissions. The study was conducted without conflict of interest.
MAIN CAUSES OF HOSPITAL RE-ENTRY FOR ALCOHOL LIVER PATIENTS IN JALISCO
HISTOLOGIC CHANGES IN THE LIVER ASSOCIATED TO OBESOGENIC DIET AND CHRONIC ALCOHOL INTAKE IN MICE
Introduction. Liver cirrhosis is one a most frequent causes of death in Mexico. Chronic alcohol intake is among the main etiologies for liver disease and is highly associated to cirrhosis mortality. At the same time Mexico is the first place worldwide in prevalence of obesity. Although both causes of liver disease coincide epidemiologically, no characterization of their interaction is available. We aimed to describe the interactions of a high fat diet (HFD) and alcohol intake at the histopathologic level in the liver. Aim. To identify histopathological changes in the liver associated with a HFD concomitantly with a chronic alcohol intake in mice. Material and methods. Six groups of C57BL/ 6, 8 week-old, male mice were obtained: control (C), ethanol (EtOH), high fat diet (HFD), ethanol + HFD (EtOH + HFD), these groups received 4 months of treatment. (HFD&EtOH): 1° HFD followed by 2° etanol and (EtOH&HFD): 1° ethanol followed by 2° HDF: these two groups received the first treatment for 4 months followed by the second treatment for another 4 months. Results. Histopathologic changes were observed in the liver depending on the treatment received. EtOH group showed slight architectural changes compared to C but did not show steatosis. HFD had microvesicular-focal steatosis located in hepatocytes by the portal area (TP). EtOH + HFD exhibited a worsen impairment in architecture compared with HFD showing microvesicular-focal steatosis in hepatocytes located by the TP. In contrast HFD & EtOH showed microvesicular-focal steatosis in hepatocytes by the central vein (VC), whereas EtOH&HFD had macrovesicular-difuse steatosis in hepatocytes at both locations. No signs of fibrosis were observed. Conclusion. Changes in liver architecture depend on the insults received as well as the interaction between them; specific patters of liver damage according to both the insult and the hepatocyte location among the liver acinus were shown without fibrosis. In mice the worst damage was caused by the chronic alcohol intake followed by a HFD. Funded by: Estímulo "Antonio Ariza Cañadilla" para la investigación en hepatología. CONACyT CB-221137. Background. The grade and severity of the hepatic failure (steatosis, fibrosis and cirrhosis) caused by diet high fat or chronic alcohol consumption or both in humans is few known, so it is necessary reproduce this condition in experimental model. Objective. Evaluate the hepatic steatosis and determine if only one or both insult (high fat diet and alcohol consumption) reproduce this pathological condition. Material and methods. We use 30 mice bread C57/BL6, 20 g of weight and 8 weeks of age. The animals were separated in 5 groups (G1 to G6) as mentioned below: G1: sham, G2: ethanol at 20% (OH 20%), G3 high fat (HF), G4: both treatments in the same time (OH20% + HF), G5: first treatment OH20% (4 months) + 2nd. treatment HF (6 months), and G6: 1st treatment HF (4 months) + 2nd treatment OH 20% (6 months). Weight gain, drink and food were measured weekly. At 6 months the animals were anesthesied to obtained blood sample and laparotomy for evaluated the abdominal organs (e.g. liver, stomach, gut, kidneys, perirenal and subcutaneous adipose). Results. No different was observed in all groups respect to the water or OH consumption. The liver injury was more evident in G5 compared to others groups. The gain weight in G3 to G6 it was greater with respect to G1 (sham). Conclusions. The alcohol consumption induced susceptibility to liver injury and then HF diet maintenance this process. The authors declare that there is no conflict of interest. This research was finance by UNAM-PAPIT TA200515 y IA 203113. Background. Nonalcoholic fatty liver disease (NAFLD) is observed in 30% of Mexicans. Guidelines suggest perform non-invasive markers of liver fibrosis in all subjects with NAFLD. However, this information is based in moderate quality information from non-prospective studies, and not validated in Latin population. Aim. to assess the utility of non-invasive methods for detection of advanced liver fibrosis in patients with NAFLD. Secondary objectives are to determine the proportion of patients that went to a specialist after receiving the diagnosis, and to describe which non-invasive method is related to an increased seek of medical attention or treatment. Material and methods. Patients from a regular check-up from June 2013 to June 2015 were prospectively enrolled, and followed during one year after diagnosis of NAFLD (NCT01874249). Inclusion criteria comprised subjects with BMI ≥ 27 kg/m 2 , liver steatosis by sonography, and exclusion of significant alcohol consumption. Patients were randomly allocated in one of five groups: receive personal counseling about NAFLD (A), interactive information about the risk of NAFLD (B), information about liver fibrosis status using NAFLD score (C); information about liver fibrosis using NAFLD score and FibroScan (D); information about liver fibrosis using FibroScan (E). Patients were contacted six months and one year later to obtain information about specialized medical care, or therapeutic strategies for NAFLD. Results. 1,213 patients were included (82% male), mean age 47 ± 9 years, and BMI 30 ± 4 kg/m². Advanced fibrosis was diagnosed in 0% (AB); 12% (C); 10.7% (D); 11.5% (E) (P < 0.05). After receiving diagnosis for NAFLD or liver fibrosis status, the group with the higher proportion of patients seeking specialized medical care or receive treatment was group D (44%), followed by group C, B, E and A (38%, 37%, 35%, 21% respectively) (P < 0.05).
HEPATIC STEATOSIS PRODUCED BY DOUBLE INSULT (DIET AND ALCOHOL): EXPERIMENTAL MODEL
UTILITY OF NON-INVASIVE METHODS TO DIAGNOSE ADVANCED FIBROSIS IN NON-ALCOHOLIC FATTY LIVER DISEASE. A RANDOMIZED CLINICAL CONTROLLED
Conclusion. An important number of overweight/obese asymptomatic subjects are not properly detected. The lack of systematic assessment of liver fibrosis has deleterious impact. Increase counseling or perform non-invasive markers for fibrosis enhanced the proportion of subjects seeking management for NAFLD. However, many patients will not seek medical attention or receive any kind of treatment; therefore, it is important to design a method to routinely diagnose and treat patients even on the first visit to the physician.
PREVALENCE OF NONALCOHOLIC FATTY LIVER DISEASE AND INSULIN RESISTANCE IN PEDIATRIC PATIENTS WITH OVERWEIGHT AND OBESITY
Background. Obesity has become one of the major health problems in pediatric population, and it is associated with Nonalcoholic Fatty Liver Disease (NAFLD); however, the prevalence is highly variable and the biochemical characteristics associated. Objective. To determine the prevalence of NAFLD and biochemical alterations in pediatric patients with overweight and obesity. 
SYSTEMIC LEVELS OF IL-4 DECREASE ACCORDING TO THE SEVERITY OF NON-ALCOHOLIC FATTY LIVER DISEASE IN OBESE PATIENTS
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Introduction. Proinflammatory cytokines have been shown to increase in obese individuals with non-alcoholic fatty liver disease (NAFLD). However, it is still unclear whether the systemic concentrations of anti-inflammatory mediators are also affected in these patients. Goals. To examine serum levels of the anti-inflammatory cytokine interleukin 4 (IL-4) in 101 obese women and men (BMI > 30 kg/m 2 ) with different grades of NAFLD. Materials and methods. Obese subjects were subjected to abdominal ultrasound imaging using a convex multi-frequency Figure 1 . Serum IL-4 significantly decreases as the steatosis degree increases. Severity of NAFLD was defined by abdominal ultrasound imaging using a convex multi-frequency transducer in gray scale. Data are presented as mean ± standard deviation. Differences were considered significant when P < 0. transducer in gray scale for establishing the severity of NAFLD. Blood samples were obtained after overnight fasting for further estimation of total cholesterol and triglycerides, tumor necrosis factor alpha (TNF-α), insulin, glucose, and the level of insulin resistance by HOMA-IR. Serum levels of IL-4 were also determined examining its association with the severity of NAFLD.
Results. Serum levels of IL-4 were significantly lower in NAFLD obese subjects than in obese individuals without NAFLD (48.13 ± 14.09 pg/mL vs. 71.46 ± 8.25 pg/mL, respectively). Besides being inversely correlated with serum TNF-α, reduced values of IL-4 were significantly related to hyperinsulinemia (r = -0.682). Interestingly, IL-4 progressively decreased as the severity of NAFLD increased (Figure 1 ). Conclusions. Systemic levels of IL-4 are clearly reduced in obese patients with severe NAFLD as compared with obese subjects without NAFLD, while also showed a significant correlation with a state of hyperinsulinemia independently of obesity. The clinical utility of serum IL-4 to identify obese patients at higher risk of developing NAFLD remains to be evaluated. This work was supported by grant no. 129316-M from CONACyT to GE. Background. Liver damage secondary to Non Alcoholic Fatty Liver Disease (NAFLD) is considered of great importance because of its close relationship with insulin resistance, diabetes mellitus (DM) and obesity, and it has direct complications, such as steatohepatitis nonalcoholic (NASH), cirrhosis or hepatocellular carcinoma. Aim. Determine the relationship between time of the diagnosis of DM 2, and the presence of liver damage in patients from DiabetIMSS clinic, HGZMF No. 1 IMSS Pachuca, Hidalgo. Material and methods. Descriptive, prospective, cross-sectional study which included patients 18 years old and more, who came to the DiabetIMSS clinic. The sample for this study was randomly selected, excluding those who had previous risk factors for hepatitis C, alcoholic liver disease, and other liver diseases. The total sample obtained was 40 patients, 34 females and 6 males, and Liver Function Test (LFT) and liver ultrasound were obtained. Liver damage evidence was analyzed in correlation with the time of diagnosis of diabetes mellitus with the Chi Square test. Results. The age range studied was 26 to 79 years, it was concluded that 72% of the population, have been recently diagnosed with Diabetes Mellitus (0 to 5 years), 50% of the population were obese, 38% had overweight, and only 12% presented normal weight. As for indicators of liver damage in women, AST was elevated in 82.35%, while in men it was raised in 50%, and considering degree of steatosis reported Figure 1 . Circulating levels of IL-1β appear to increase in accordance to the degree of steatosis. Severity of NAFLD was defined by abdominal ultrasound imaging using a convex multi-frequency transducer in gray scale. Data are presented as mean ± standard deviation. Differences were considered significant when P < 0. The obesity grade had a week positive correlation with the risk of significant fibrosis (r = 0.21, P = 0.04). The dysglycemic state had a strong positive correlation with the risk of significant fibrosis (r = 0.50, P < 0.0001).
SEVERITY OF NON-ALCOHOLIC FATTY LIVER DISEASE ASSOCIATES WITH HIGH SERUM LEVELS OF INTERLEUKIN 1 BETA IN OBESE PATIENTS
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RELATIONSHIP BETWEEN TIME OF DIAGNOSIS AND PRESENCE OF LIVER DAMAGE IN DIABETES MELLITUS 2 PATIENTS FROM DIABETIMSS CLINIC
Conclusions. Obesity and diabetes are associated with the risk of significant liver fibrosis according with NAFLD score. Type 2 diabetes is the predictive factor with the strongest association strength to develop significant liver fibrosis. 
SEVERITY OF NON-ALCOHOLIC FATTY LIVER DISEASE AND METABOLIC RISK PHENOTYPE IN OBESE PATIENTS
Background and aims.
Obese patients with metabolic syndrome (MS) have a greater risk to developing non-alcoholic fatty liver disease (NAFLD); however, the influence of the metabolic phenotype over the degree of NAFLD progression is not clear. The aim of the present study is to evaluate histological progression of NAFLD associated to the metabolic phenotype in obese patients. Material and methods. Design. Cross-sectional and observational study. Obese patients (n = 13) treated at the Bariatric Surgery Department at CMN 20 de Noviembre, ISSSTE; candidates for bariatric surgery, without consumption of alcohol or other hepatotoxic agent. Patients were classified as metabolically healthy obese (MHO) if < 3 MS criteria; and metabolically unhealthy obese (MUO) with at least 3 MS criteria. At the time of surgery, liver biopsies were obtained, and further evaluated by two different pathologists experienced in liver damage, blinded to clinical patient's information (acceptable intraclass correlation coefficient was verified). We considered advanced NAFLD damage with any of the following criteria: steatosis larger than 66% in the presence of severe ballooning degeneration; or severe necro-inflammatory changes; or fibrosis score II or greater. Statistical analysis through chi-square test. Results. 13 patients were included, and classified as MHO (n = 9; 3 men y 6 women, median age 44.8 years old) and MUO (n = 4; 2 men y 2 women, median age 40 years old); without significant differences concerning the anthropometric parameters body mass index and abdominal circumference. A greater degree of steatosis was observed in patients with MUO phenotype vs. MHO (55.0 vs. 37.1%, respectively; p <0.05) . Interestingly, all patients with MUO phenotype (100%) showed at least one criterion of advanced NAFLD damage, showing fibrosis score II-IV. MHO group showed advanced NAFLD damage in two cases (28.6%); one of them with fibrosis score III. In general, differences were statistically significant (p<0.05). Conclusions. Results suggest that metabolic phenotype is significantly associated with severity of NAFLD, as determined by liver biopsy, in obese population. The authors declare that there is no conflict of interests. Introduction. Hemoglobin expression is regulated by oxidative stress; its increase has been related to the inhibition of HepG2 cells oxidation and the degree of steatosis in murine models. Ac-tually the association of hemoglobin high levels in patients with nonalcoholic fatty liver disease is currently unknown. The aim of this study was to determine the association of hemoglobin serum levels with the degree of steatosis and fibrosis in patients with nonalcoholic fatty liver. Material and methods. A crosssectional study nested in a randomized clinical trial (NCT01874249), which evaluated 1,203 patients with nonalcoholic fatty liver disease determined by ultrasound was performed. The degree of steatosis was classified as mild, moderate and severe. Serum hemoglobin concentrations were determined. In 441 patients transient elastography was performed to assess the degree of fibrosis. To determine the association between serum hemoglobin levels and the degree of steatosis an analysis of oneway ANOVA adjusted for smoking and body mass index was performed. Results. 82% (n = 983) of the sample were male with an average age of 48 ± 9 years and a body mass index of 30.6 ± 3.6 kg/m 2 . Smoking prevalence was 26.7% (n = 321). According to ultrasound 36.6% (n = 440) of patients had mild steatosis; 33.1% (n = 398) moderate and 6.2% (n = 74) severe. Of the patients evaluated with transient elastography 5.1% (n = 63) had some degree of fibrosis (> 7 kPa). The average concentration of hemoglobin was 15.7 ± 1.2 mg/dL. In comparing averages, increased hemoglobin levels were significantly associated with the degree of steatosis, having mean concentrations of 15.6 ± 1.2 mg/dl for mild steatosis, 16.1 ± 0.9 mg/dL for moderate and 16.02 ± 1.2 mg/dl were for severe (p < 0.001) (Figure 1) . When comparing the levels of hemoglobin in the presence of fibrosis, no significant associations were found. Conclusions. In patients with nonalcoholic fatty liver disease high levels of hemoglobin are related to the degree of hepatic steatosis determined by ultrasound. However they were not associated with the presence of fibrosis. Introduction. Visceral adiposity index (VAI) is a mathematical model associated with metabolic and cardiovascular diseases in adults. Previous study on pediatric population failed to demonstrate any association of VAI with metabolic risk. In parallel, we adapted VAI components to pediatric population (VAI P ), but its association with metabolic or cardiovascular risk, has not been yet evaluated. NAFLD represents the liver expression of metabolic syndrome and transaminases are usually elevated in this condition. Little is known in childhood obesity and less its association with VAI P . Aim. (VI.14) Figure 1 . (VI.14) Figure 1 . (VI.14) Figure 1 . (VI.14) Figure 1 . (VI.14) Figure 1 .
ASSOCIATION OF HEMOGLOBIN SERUM LEVELS IN NON ALCOHOLIC FATTY LIVER DISEASE
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CORRELATION BETWEEN BODY MASS INDEX AND LIVER DAMAGE IN CHILDREN POPULATION WITH
11 years) was carried out, 30 of them with obesity, acanthosis nigricans and Tanner stage < 2. Pearson correlation and ANOVA were done. SPSS v.22 was used. p < 0.01. Results. VAI P was adjusted considering children between < 10 and ≥ 10 years of age, in order to avoid the bias of puberty metabolic changes. A significant moderate correlation was found between VAI P and HOMA-IR (r = 0.452, p = 0.003), Matsuda (r = -0.366, p = 0.019), ALT (r = 0.410, p=0.008), and GGT (r = 0.397, p = 0.010). Children with higher VAI P and abnormal HOMA-IR (Figure 1c) , had higher levels of hepatic enzymes than healthy children (Figure 1a) . A paradoxical third group with higher HOMA-IR and normal VAI P had higher glucose than the other groups, suggesting an intermediate step. Conclusions. The adjusted VAI P correlates with HOMA-IR, Matsuda and hepatic enzymes. It could be helpful for identifying children at risk for cardiometabolic diseases. Since glucose is higher in paradoxical group, this variable could be included to improve the prognosis tool. CONACyT SALUD-2012-01-181786.
IMPROVEMENT OF THE METABOLIC PROFILE AND LIVER FUNCTION TESTS IN OBESE PATIENTS AFTER BARIATRIC SURGERY
HIGUERA-DE LA TIJERA F,* CALLE-RODAS DA,** HIGUERA-DE LA TIJERA F,* CALLE-RODAS DA,** HIGUERA-DE LA TIJERA F,* CALLE-RODAS DA,** HIGUERA-DE LA TIJERA F,* CALLE-RODAS DA,** HIGUERA-DE LA TIJERA F,* CALLE-RODAS DA,** VANEGAS-HERRERA JA,*** CRUZ-ESTRADA A,** VANEGAS-HERRERA JA,*** CRUZ-ESTRADA A,** VANEGAS-HERRERA JA,*** CRUZ-ESTRADA A,** VANEGAS-HERRERA JA,*** CRUZ-ESTRADA A,** VANEGAS-HERRERA JA,*** CRUZ-ESTRADA A,** CAMACHO-AGUILERA J,**** SERVÍN-CAAMAÑO AI** CAMACHO-AGUILERA J,**** SERVÍN-CAAMAÑO AI** CAMACHO-AGUILERA J,**** SERVÍN-CAAMAÑO AI** CAMACHO-AGUILERA J,**** SERVÍN-CAAMAÑO AI** CAMACHO-AGUILERA J,**** SERVÍN-CAAMAÑO AI** , , , , , *** *** ***Introduction and aims. Obesity is a worldwide health care problem, it is related to non-alcoholic steatohepatitis (NASH). In countries with high prevalence of obesity, NASH is the main cause of abnormal liver function tests (increase of transaminases). The aim of this study was to know the metabolic and liver function profile of obese patients and to evaluate if this profile improves after bariatric surgery. Material and methods. An observational, longitudinal, prospective, and analytic study. We collected data from obese patients before surgery and 3-month after surgery. Patients lost during follow-up were excluded. To compare between groups t Student for related samples was performed, a P ≤ 0.05 was considered significant. Results. The cohort included 98 obese patients, 83 female (84.7%). The average of age was 40.2 ± 1.0 year-old. Diabetics 16 (16.3%), prediabetics 33 (33.7%), normoglycemic 49 (50%). Two diabetics (12.5%) received metformin and 14 (87.5%) metformin + other. Twenty four prediabetics (72.7%) received metformin. The analysis to compare before and after bariatric surgery in the different subgroups is shown in tables 1-3. Conclusions. The weight loss by bariatric surgery improves the metabolic and liver function profile, it is noteworthy the improvement in ALT and platelets, as possible indirect markers related to hepatic/systemic inflammation. Introduction. The new tools for diagnosis of liver fibrosis must be compared to biopsy, the diagnostic standard, which has shortcomings related to scattering of fibrosis within the organ itself and between individuals. This leads to diagnostic uncertainty, which furthermore impacts the accuracy in the calibration of non-invasive tools. Objective. To determine the scattering degree of fibrosis in a CCl 4 induced murine model. Material and methods. Four groups of 4 male Wistar rats were injected with 33% CCl 4 in olive oil at 1 μL/g, in doses adjusted to weekly weight gain. Sacrifices were made at 4 (T1), 6 (T2), 10 (T3) and 13 (T4) weeks. Livers were collected in formaline and stained with Masson Trichrome. 10 4x observations were made in 3 different zones of the liver and evaluated with METAVIR score. A χ 2 test between F observed and F expected was performed (p < 0.05). Results. F observed was different from F expected (p < 0.01). The distribution range of each T's fibrosis overlaps with the adjacent time, in T1-T2 and T3-T4 (Figures 1-2) . T3 has the highest scattering and the biggest distance to the expected value, T2. Conclusions. The induction times do not render a predominant stage of fibrosis. Scattering is preeminent in intermediate stages, in accordance with the substantial inaccuracy described for the new diagnostic techniques. This suggests that the problem in discerning intermediate stages could be due to poor calibration techniques related to fibrosis scattering. Introduction. In April / 2015 VII Workshop was held Baveno. Updated definitions were given and transient elastography (TE) was introduced into clinical practice. Compensated advanced chronic liver disease (CACLD) was proposed to reflect that, the spectrum between advanced fibrosis and cirrhosis is continuous in asymptomatic patients. TE liver stiffness is sufficient to suspect CACLD in asymptomatic subjects with known etiology. A measure < 10 kilopascals (kPa) in absence of clinical signs, excludes CACLD, 10-15 kPa suggest that, but need further testing for confirmation and > 15 kPa are highly suggestive. Objective. To investigate presence of liver damage in patients with Chikungunya fever from the recent outbreak in Mexico, 2015. Material and methods. We studied patients at the Clinical Hospital "Dr. Roberto Nettel Flores", in Tapachula, Chiapas, with acute febrile illness, suggestive of Chikungunya virus (CHIKV) infection. RT-qPCR or IgM by ELISA confirmed CHIKV infection. After patient's written informed consent, 5 mL of blood were withdrawn and clinical manifestations were recorded. We measured: alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), γ-glutamyl transferase (GGT), total bilirubin, direct bilirubin, indirect bilirubin, cholesterol and total protein in serum samples. Results. We studied 40 patients CHIKV (+), 78% women, mean age 39 ± 17.7 years. Common symptoms were: myalgia, arthralgia, headache and chills in 98-85% of cases. There were no differences in the proportion of symptoms between the groups analyzed by RT-qPCR or IgM except lymphadenopathy, present mainly in IgM group (p = 0.01). In these patients infected with CHIKV, there was no statistical difference in liver function tests between the two groups. However, analyzed individually, AST levels were elevated in 17 patients (42.5%) and ALT in 13 patients (32.5%). GGT and ALP were elevated in 9 (22.5%) and 7 (17.5%) patients, respectively. Interestingly, a young patient had 5-fold increase in ALT and AST and 2 times in ALP and GGT, without clinical remarks. The average levels of ALT in patients with conjunctival hyperemia were statistically higher compared to patients without this sign (p = 0.02). Bilirubin tests were normal. Only three patients had subtly elevated cholesterol levels. Total proteins were measured mainly in the IgM group due to sera scarce, and the results were between the reference levels. Conclusions. We found no abnormal median values of the studied enzymes in these patients, and the other biochemical parameters, in contrast with the published data in other populations.
IT IS POSSIBLE TO APPLY BAVENO VI TO SUSPECTED COMPENSATED CIRRHOSIS
Further studies are required in order to define the role of liver function in this infection. This work has been totally subsidized by PROMEP/103.5/15/3344 project.
The authors report no conflicts of interest. Introduction. Pre-hepatic portal hypertension is a rare disease with prevalence ranging between 0.7 and 3.7 per 100,000 population. Ectopic colonic varices are even a rarer clinical manifestation, the cause is portal hypertension and the localization is usually in rectosigmoid junction and cecum with more frequency. The aim of this paper is to present the clinical case of a patient with low gastrointestinal bleeding, secondary to colonic varices as clinical manifestation of pre-hepatic portal hypertension. Case report. 47-year-old male with a history of type 2 diabetes of 10 years of evolution, acute pancreatitis 6 months prior to the current clinical picture. He presented haematochezia more than 6 events per day, with hemodynamic alteration manifested by fainting, he decreased hemoglobin levels to 3 g/dL and required transfusion with multiple red cell concentrates. Endoscopy reports gastric varices IGV2 satisfactorily treated with injection of cyanoacrylate, however, he persisted with hematoquezia so an angiography was performed so as an angiotomography that reported dolic splenic artery and splenomegaly. The colonoscopy reported colonic varices in splenic flexure with no data of recent bleeding, the endoscopy capsule corroborated colonical varices and excluded other causes of bleeding. The patient had no new bleeding event, and was discharged with conservative management. Conclusions. Ectopic varices as a complication of extrahepatic portal hypertension is a rare manifestation, have been documented in the literature less than 100 clinical cases of these, only 17 cases with varices of colonic location, the cases of colonic varices localized in left colon are outstanding. The treatment is not well established but it ranges from conservative management to partial or total colon resection. We found it important to present the case of the patient, because the colonic varices cause several bleeding and it only occurs in 1 to 5% of all episodes of variceal bleeding, causing massive bleeding with high mortality of up to 40%. Colonic varices should be considered in the differential diagnosis in patients presenting with gastrointestinal bleeding. Introduction. Liver disease nutritional status determines evolution. In recent studies it has been observed that the genotype is determinative of the response to treatment in patients with HCV. It needs to be known if other features contribute to evolution, however, it has not been reported in the literature that nutritional status variables described are related to this situation. According to the known genotypes, they were divided into 3 groups: Genotype 1a (n = 30), Genotype 1b (n = 28) and Genotype 2b (n = 7). Differences were found in BMI (p = 0. The study shows that individuals with genotype 1b are more likely to gain weight from the accumulation of body fat, which is a risk factor for the development of liver cirrhosis. It's important to continue with more studies to confirm these findings.
COLONIC VARICES AS A COMPLICATION OF PRE-HEPATIC PORTAL HYPERTENSION DUE TO ACUTE PANCREATITIS AND PORTO-SPLENO THROMBOSIS
ANTHROPOMETRIC, BIOCHEMICAL, CLINICAL AND DIETETIC INDICATORS RELATED TO THE RISK OF MALNUTRITION IN HOSPITALIZED PATIENTS WITH LIVER CIRRHOSIS. TWEAKING SCREENING TOOLS
ANTHROPOMETRIC AND BIOCHEMICAL CHARACTERISTICS OF PATIENTS WITH LIVER CIRRHOSIS BY HEPATITIS C VIRUS (HCV) ACCORDING TO GENOTYPE. AN EXPLORATORY STUDY
RODRÍGUEZ
DETECTION OF WINDOW PERIOD HEPATITIS C AND OCCULT HEPATITIS B INFECTIONS IN BLOOD DONORS FROM VERACRUZ
LÓPEZ-BALDERAS N,* BRAVO-SARMIENTO E,** LÓPEZ-BALDERAS N,* BRAVO-SARMIENTO E,** LÓPEZ-BALDERAS N,* BRAVO-SARMIENTO E,** LÓPEZ-BALDERAS N,* BRAVO-SARMIENTO E,** LÓPEZ-BALDERAS N,* BRAVO-SARMIENTO E,** HERNÁNDEZ-ROMANO P** HERNÁNDEZ-ROMANO P** HERNÁNDEZ-ROMANO P** HERNÁNDEZ-ROMANO P* Background. Mexico is a low prevalence region for hepatitis B and C, however hepatitis C is a major cause of cirrhosis and liver transplant candidates in the country. In Veracruz, liver diseases are the leading cause of death in men aged 35 to 44 years and the second in men aged 45 to 64. The reported prevalence for hepatitis B and C in blood donors from Veracruz was of 0.11% and 0.72% respectively, being Papaloapan the highest prevalence region for both infections in the state. Aim. To determine the occurrence of window period hepatitis C and occult hepatitis B infections (OBI) in blood donors in the Centro Estatal de Transfusión Sanguínea de Veracruz (CETS-Veracruz). Material and methods. A retrospective and cross-sectional study from blood donors attended in CETS-Veracruz in the period of 2010 to 2014 was carried out. Serological screening was performed using VITROS 3600 ECi / ECiQ Immunodiagnostic System (until 2013) and ARCHITECT Plus i2000 SR (2014) which included total anti-HBc. In the 2010-2012 period nucleic acid amplification tests (NAT) were intermittently applied to 7,596 samples using Roche COBAS Amplicor and in 2014 TI-GRIS Procleix was used. Results. Three probable hepatitis C window period infections were found, but only one was confirmed from frozen plasma, which has the risk factors identified previously, such as being fisherman and coming from the Papaloapan region (Alvarado). The prevalence for anti-HBc obtained in 2014 was 0.86%. Within the anti-HBc positive samples and negative for HBsAg, 19 were analyzed by NAT and one was positive (OBI case). Conclusions. There is controversy about the costs of NAT implementation in blood banks in Mexico since the results are very heterogeneous. Our results demonstrate the usefulness of NAT in Veracruz, because in the very few samples analyzed it was possible to identify an OBI case and a window period hepatitis C infection (two more putative). It is worth mentioning that each positive blood unit to hepatitis B and C can infect up to 4 recipients of blood components. This study was supported by the Health Secretariat of Veracruz State through the CETS-Veracruz.
EPIDEMIOLOGY OF INFECTION BY HEPATITIS C VIRUS IN THE GASTROENTEROLOGY SERVICE, ISSSTE TLAXCALA
PEÑA-DÁZ P*, PILIADO-PAEZ H*, AGUILAR-RAMÍREZ JR** PEÑA-DÁZ P*, PILIADO-PAEZ H*, AGUILAR-RAMÍREZ JR** PEÑA-DÁZ P*, PILIADO-PAEZ H*, AGUILAR-RAMÍREZ JR** PEÑA-DÁZ P*, PILIADO-PAEZ H*, AGUILAR-RAMÍREZ JR** PEÑA-DÁZ P*, PILIADO-PAEZ H*, AGUILAR-RAMÍREZ JR** *HOSPITAL GENERAL ISSSTE TLAXCALA, TLAXCALA. ** PRIVATE PRACTICE MEXICO CITY.
Background. Hepatitis C virus infection occurs in 3% of the world's population, 85% develop chronic infection, cirrhosis in 20% and 4% of hepatocellular carcinoma. Objectives. To determine the clinical and epidemiological characteristics on reagents HCV patients sent to the Unit. Material and methods. A retrospective, descriptive, longitudinal study was conducted over a period of three years (January 2013 -January 2016) of patients referred to the Departmet of Gastroenterology as reagents to HCV; which they underwent confirmatory test and later with baseline CRP quantitative determination of genotype. Thirty-seven patients (prevalence of the 5th decade of life) was included, was confirmed by PCR test to 83.7% (31 patients). In the positive genotype it was determined. Results. Thirty-one patients in total, 9 males, (29.1%) and 22 women (70.9%). The genotypes found were: 1a -38. 7%, 32.2% 1b, 2b -19 .3%, and 9.6% indeterminate. The genotype distribution was: 1a 25.8% women, 12.9% men, 22.5% women 1b, 9.6% men. Genotype 2b -12.9% women, ad 6.2% men. The transfusion was found 74.1% and was the main cause of infection. The second cause of infection was being worker health -9.6% (nurses). As a third cause family history -6.4% and finally tattoos and pearcing 3.2%. Unknown cause with the same 3.2%. During the study period they were found and corroborated 3 cases of hepatocellular carcinoma. Conclusions. In this study we found a high prevalence of the risk G allele (heterozygous CG or homozygous GG) of PNP-LA3 gene in Mexican population. However, due to the low proportion of subjects with obesity, it is necessary to increase the sample size to determine the prevalence of PNPLA3 genotypes in this subgroup. Background and aim. Although management of patients with uncomplicated ascites includes a low sodium intake and diuretics, there is limited information about how frequently patients receive restriction as part of their treatment. The aim of the study was to identify the frequency of dietary sodium restriction in ambulatory cirrhotic patients. Material and methods. Cross-sectional study in ambulatory patients with cirrhosis, who were studied at the Gastroenterology Department of Centro Médico Nacional Siglo XXI. Anthropometric, clinical-nutritional, biochemical, and dietetic parameters were assessed. Energy, protein and sodium dietary intake were estimated based on a 24-h dietary recall and food frequency questionnaires. Child-Pugh index was estimated and the use of diuretics registered. Results. One hundred twenty-eight patients with liver cirrhosis were included, with median age of 56.66 ± 13.66 years. They were classified according to the Child-Pugh index as A = 56, B = 58 and C = 14, and according to the severity of ascites they were classified as without ascites (n = 80), mild (n = 3), moderate (n = 38) and severe (n = 7). Frequency of dietary sodium restriction was 51.66% (n = 66). The average daily intake of sodium was 45.62 ± 29.1 mEq (reference value = 86.9 mEq). Sodium blood levels were under the reference value in 7/34 (20.6%) patients with dietary sodium restriction and diuretics, compared to 1/32 (3. 
PRETREATMENT SCORING MODEL (PRET-SM) AS A PREDICTOR OF SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PATIENTS WITH CHRONIC INFECTION OF HEPATITIS C VIRUS (HCV) GENOTYPE 1
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LYSOSOMAL ACID LIPASE DEFICIENCY IN PATIENTS SENT TO VALUATION OF LIVER TRANSPLANT, A STUDY OF CASE AND CONTROLS
Background. Deposition disease cholesteryl ester (DDCE) is caused by deficient or null activity of the lysosomal acid lipase (LAL) levels < 40 pmol/hr/spt, by LIPA gene mutation. The prevalence in Caucasians and Hispanics is (1:90,000/170,000). Adults may have hypertransaminasemia, dyslipidemia (HDL-C levels < 40 mg/dL and LDL-C > 130 mg/dL), microvesicular steatosis, fibrosis and cirrhosis may have been diagnosed as cryptogenic cirrhosis (CC). Aim. Identify the prevalence of LAL-D in Patients evaluated for orthotopic liver transplantation (OLT) and compare levels of LAL with a group of healthy controls. Material and methods. Retrospective, transversal and descriptive study; Patients were analyzed and compared, for evaluation and randomly matched from pre OLT, post OLT and a group of healthy controls. Demographic and biochemical variables (LAL levels and lipid profile) were analyzed. Means, standard deviations, and ranges descriptive variables, T-test for related samples and test for nonparametric correlations Pearson correlations were used. SPSS v21.0 statistical analysis, p < 0.05 statistically significant. Results. Control healthy group (group 1) 18 patients (14%), post-OLT 74 (group 2) (57%) and pre-OLT (group 3) 38 (29%): 130 patients divided into three groups were included. 66 women (51%); mean age 51 ± 13 years; average levels of lipase 178 pmol/hr/ spt ± 118; average HDL-C 43 mg/ dL ± 15 and mean LDL-C 88 mg/dL ± 36; Were the mean lipase levels 301 pmol/hr/spt. Similar demographic characteristics to analyze each group; average levels in each group was 1: 301 ± 170, group 2: 189 ± 122 and 3: 152 ± 73. Between correlation etiology and lipase levels (0.002), the study group and lipase levels (0,000) and lipase levels and HDL -c (0.001) was found.
Conclusions.
Lipase levels and lipid profile were lower in the group Pre and Post OLT compared to the control group. With direct correlation to the levels of lipase and each study group and etiology of cirrhosis was obtained.
FIBROSIS REGRESSION AFTER TREATMENT WITH TRIPLE THERAPY IN PATIENTS WITH LIVER TRANSPLANT FOR HEPATITIS C VIRUS
Background. HCV recurres immediate and universally in patients post-orthotopic liver transplantation (P-OLT) with detectable RNA at transplant. Triple therapy (TT) based IFN-peg + RBV+ protease inhibitor (PI) is indicated in HCV genotype 1 (GT1), with SVR up to 75%. If the HCV is eradicated, has been a regression in the degree of inflammation and hepatic fibrosis. Aim. Determine the degree of fibrosis in patients P-OLT with HCV recurrence before and after treatment with TT. Material and methods. Retrolective and descriptive study. Six patients were analyzed P-OLT HCV recurrence and fibrosis treated with TT (IFN-peg + RBV + IP), transient elastography (ET) (Fibroscan®) was performed after sustained viral response (SVR) and compared with histopathology prior to treatment. Demographic, clinical, biochemical variables were analyzed. For descriptive variables mean, range and standard deviation were used. For correlation of related samples T Student. Statistical analysis with SPSS v21.0. Statistical significance at P < 0.005. Results. Six patients were included. 100% men, mean age 53 ±9 years; GT1b 5 (83%), IL-28b. Immunosuppression with tacrolimus 3 (50%), cyclosporin-A 3 (50%). All were treated with TT and got 100% SVR. Comparing the histological pattern prior to treatment and post treatment ET regression of fibrosis was found (3 patients F3 to F1, 2 patients F2 to F1 and 1 was kept in F3). A rapid viral response with greater regression of fibrosis after treatment was correlated (P = 0.02).
Conclusions.
TT treatment is effective in eradicating HCV and regression of fibrosis in patients P-OLT with 100% SVR at 24 weeks.
STEATOSIS AND FIBROSIS IN POST-LIVER TRANSPLANT PATIENTS AND ITS RELATION TO NUTRITIONAL STATUS
scribe the frequency of steatosis and fibrosis in patients post liver transplant and its relation to nutritional status. Material and methods. In a cross sectional descriptive exploratory study which included post liver transplant patients, it was measured weight, height, waist circumference, hip circumference and skinfold, blood chemistry and lipid profile. It was measured the degree of steatosis (S0 to S3) and fibrosis (F0 to F4) with transient elastography (Fibroscan). The data analysis was performed using SPSS v.20. Results. 22 post liver transplant subjects (50% women) with an age range of 34-68 years (median 56.5) were evaluated. These subjects had among 2 months to 11 years of transplanted. Comorbilities such as diabetes and hypertension were observed on the 22.7% of the individuals, 31.7% presented a degree of fibrosis and 41% a degree of steatosis. It was observed that the individuals with low steatosis presented higher weight (p = 0.038) and changes on creatinine levels (p = 0.005), BUN (p = 0.047) and urea (p = 0.047) vs. steatosis abscence. On the other hand, individuals with severe fibrosis (F3 and F4), presented an arm circumference and suprailiac skinfold over the normal parameters (p = 0.031) and (p = 0.033). There was no statistical significance in another degree of steatosis and fibrosis or any other biochemical or anthropometric parameter. Individuals began to present steatosis approximately 3 months after surgery. Conclusion. A high percentage of post transplanted individuals have some degree of steatosis and fibrosis, as well as trend changes in anthropometric and biochemical parameters.
IMPACT ON THE QUALITY OF LIFE IN PATIENTS IN WAITING LIST FOR ORTHOTOPIC LIVER TRANSPLANTATION (OLT) AFTER A NUTRITIONAL INTERVENTION
Background. The incidence of obesity in Mexico has increased; thus the prevalence of obese candidates for liver transplantation (LT) is greater. Because of this, it is important to keep track post orthotopic liver transplantation (LT) in obese and assess whether outcomes are appropriate. Aim. Evaluate the implication of obesity in the evolution post LT after 24 months in comparison with a control group with normal weight. Material and methods. Fifty-two patients post LT were studied; 28 were cases of overweight/obesity (20 and 8 respectively) 15 men and 13 women; cryptogenic etiology: 9, HCV: 7, autoimmune: 5, alcoholic: 2 and others: 5; of the total 6 with hepatocarcinoma, Baseline characteristics between cases and controls were similar, although cryptogenic etiology was more prevalent in cases (28.6 vs. 22.5% p 0.05). Survival was 100 % in both groups at 24 months. BMI decreased at 3 months post-transplant in both groups but was higher in cases (2.4 vs. 1.3 , respectively) and in following 24 months, a gradual increase was observed in both groups, being higher in the control group (4.3 vs. 2.7 p 0.0001). When comparing creatinine between overweight and obese, persistent elevation was observed at 6, 12 and 24 months in obese without exceeding 1.81 mg/dL (p 0.01). The incidence of acute rejection in both groups was not significant (2 vs. 4 p 0.39). Conclusions. There were not significant differences in survival of obese patients post LT to 24 months compared with normal weight. BMI had a higher diminution in obese at 3 months and the increase was higher in normal weight at 24 months. Therefore the nutritional management should be an integral part of pre-LT and post-LT in both groups.
SARCOPENIA IN OBESE PATIENTS WITH CIRRHOSIS EVALUATION FOR LIVER TRANSPLANTATION
Background. Liver cirrhosis (LC) triggers a chronic inflammatory response and oxidative stress consistent with elevated levels of proinflammatory cytokines perpetuating the inflammatory state and causing cell damage; producing reactive oxygen species have been implicated in the induction of proteolysis in striated muscle by activating the ubiquitin-proteasome system, promoting muscle wasting in people with LC. The branched chain amino acids (BCAA) interact with the ubiquitin-proteasome system attenuating muscle wasting, and can be therapeutic aids to prevent progressive and permanent loss of fat-free mass, and therefore reduce the risk of complications of the disease, and morbidities associated (VIII.08) with surgical transplant process. Aim. To evaluate the effect of BCAA supplementation vs. a polymeric standard snack on inflammatory markers in cirrhotic patients evaluated for liver transplantation. Material and methods. Randomized clinical trial with follow up to two months. Thirty patients, 17 of which were supplemented with a semi-elemental formula vs. standard foodbased snack with the same caloric load and the same distribution of nutrients. Biochemical methods were performed by EIA in peripheral blood (MAP MILLIPLEX human kit) for: leptin, insulin, TGFa, TNFa, IL6. Statistical analysis was performed using SPSS v21 taking as significant a value of P < 0.05. Results. We found significant decrease in TNFa, leptin and resulting in decreased inflammation and anorexia. Conclusions. Supplementation with AACR-based formula had a tendency to decrease the inflammatory process in these patients. While it is necessary to increase the time of supplementation and population.
RETROGRADE CHOLANGIOGRAPHY ENDOSCOPY WITH SINGLE BALLOON ASSISTED ENTEROSCOPY (RCE-SBAE) FOR TREATMENT OF ANASTOMOTIC BILIODIGESTIVE STRICTURE IN LIVER TRANSPLANT. REPORT OF 3 CASES
Background. Endoscopic treatment of anastomotic biliodigestive stenosis is often a difficult procedure and may require percutaneous transhepatic biliary drainage or reoperation. With the introduction of assisted single balloon enteroscopy, there has been an improvement in endoscopic techniques for resolution of surgical complications in patients with altered gastrointestinal anatomy. It has led to the development of techniques for stone extraction, stenting and dilation. We present three patient cases with orthotopic liver transplantation (OLT) and biliodigestive surgery (BDS). Case report. Case 1: 38 year's old male with OLT secondary to chronic infection for active HCV. After severe bile leakage he was submitted to biliodigestive surgery with subsequent biliodigestive anastomosis stenosis. Case 2: 67 years old male with OLT secondary to non-alcoholic steatohepatitis. He presented coledochal anastomosis stenosis, with complications secondary to metallic prosthesis, who required BDS caused by the disfunction of the metallic prosthesis. Case 3: 54 years old male with OLT secondary to VHB infection, who presented coledochal anastomosis stenosis, being performed endoscopic treatment without resolution, finally submitted to BDS. During the procedure, a prosthesis was used to make viable the anastomosis, with subsequent occlusion. It was performed RCE-SBAE in the three patients. In the first two cases, pneumatic dilation was performed, achieving stenosis resolution. In the third case, the prosthesis was taken out, normal biliary anatomy was observed, without any complication. Conclusion. The RCE-SBAE had a high success rate in patients with altered gastrointestinal anatomy, so it should be considered as first-line intervention, in patients who requiered access to billary duct such as gastric by-pass with Y Roux, hepaticjejunostomy or in Whipple procedure. Background. Liver cysts are uncommon and usually asymptomatic pathology diagnosed as incidental findings on an imaging test. They are divided into two categories, parasites and nonparasitic and are subdivided into single or multiple. Simple cysts often produce symptoms when they exceed 5 cm in diameter, requiring sometimes surgical approach. Multiple cysts become relevant for its association with polycystic kidney disease and Von Hippel Lindau disease and the potential for malignant degeneration. In this review the incidence of simple hepatic cyst and polycystic disease is analyzed in the Hospital Juárez de Méx-ico. Aim. To determine the prevalence of simple hepatic cysts and polycystic disease found in the outpatient Department of Gastroenterology Hospital Juárez de México in the period from January 2015 to January 2016. Material and methods. Retrospective, descriptive study. Records of patients attending the outpatient area cyst diagnosed with Polycystic Liver Disease Simple and Service Gastroenterology, Hospital Juárez México January 2015 to January 2016 were reviewed. Results. Eight patients of which 7 (87.5%) were female and gender 1 (12.5%) male aged between 45 and 61 years old they were reported. Of which 6(75%) were found cases diagnosed with simple and 2
EPIDEMIOLOGICAL AND CLINICAL CHARACTERISTICS OF PATIENTS REFERRED FOR EVALUATION FOR LIVER TRANSPLANTATION IN TRASPLANT UNIT OF HOSPITAL GENERAL
Background and aim. Liver cancer causes over one million deaths a year, in Mexico is the fifth leading cause of death for cancer and survival is limited, among other therapeutic regimens like chemoembolization, radiofrequency, cryotherapy, surgery and transplantation are mentioned but the results have not been good. In this study is handled a patient with celecoxib and pentoxifylline, the first is a Cox-2 inhibitor with anti-inflammatory effect, antipyretic, analgesic, reduces tumor growth factors, inhibits prostaglandin, CD 44, among multiple transcription factors, NFK beta, IL 6, STAT3, JAK2, which are involved in immune response antitumor and antiangiogenic. And the second used by its anti-inflammatory, antioxidant, antifibrotic and NFK beta inhibitor effect, so the combination of both drugs suggests have synergistic and antitumor effect. Our objective is to demonstrate the good response presented in a patient with hepatocellular carcinoma with this treatment. Case report. Male 60 years old, with a history of 47 years of alcoholism, which manifests encephalopathy, jaundice, anorexia and malaise, diagnosed with cirrhosis 18 months ago, MRI, CT, eco liver and biliary tract, where it shows a large tumor that affects the entire right lobe, after 18 months of treatment at doses of celecoxib 400 mg/day and 800 mg/day of pentoxifylline, their liver function tests improved and its large tumor almost disappeared. Laboratorial changes by comparing the baseline taken and 18 months were TGO 192 18.2 U/L, TGP 115 19.4 U/L, total protein from 5.6 to 3.8 g/dL, albumin 1.8 to 3.6 g/dL, bilirubin 3.6 1.1 mg/dL, ALF 240 to 2.97 mg/L. Conclusions. The combination of celecoxib and pentoxifylline has been studied in vitro and in vivo with good response in neoplastic processes that have demonstrated an overexpression of Cox-2 especially in hepatocellular carcinoma, so that treatment with celecoxib combined with pentoxifylline synergized the response in this patient. This promising combination invites multicenter studies to know its real effectiveness. The authors declares that there is no conflict of interest. 
